Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback